Suscribirse

Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort - 27/07/22

Doi : 10.1016/j.therap.2022.07.001 
Manon Pluye a, Aurore Gouraud a, Magali Herve a, Ha Le a, Tristan Dagonneau b, Stéphane Dalle c, Judith Cottin a, Michel Cucherat a, d, Marina Atzenhoffer a,
a Service Hospitalo-Universitaire de Pharmaco-Toxicologie (SHUPT), Hospices civils de Lyon, 162, avenue Lacassagne, 69424 Lyon, France 
b Department of Medical Information, Centre Hospitalier Lyon-Sud, 69495 Lyon, France 
c Hospices civils de Lyon, Cancer Research Center of Lyon, Dermatology Department, Pierre-Bénite, France; Université Lyon 1, ImmuCare (Immunology Cancer Research), 69100 Villeurbanne, France 
d UMR 5558 CNRS Lyon, Université de Lyon, Université Lyon 1, 69003 Lyon, France 

Corresponding author. Service Hospitalo-Universitaire de Pharmaco-Toxicologie (SHUPT), Hospices Civils de Lyon, 162, avenue Lacassagne, 69424 Lyon, France.Service hospitalo-universitaire de pharmaco-toxicologie (SHUPT), hospices civils de Lyon162, avenue LacassagneLyon69424France
En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Wednesday 27 July 2022
This article has been published in an issue click here to access

Summary

Introduction

Data on adverse drug reactions (ADRs) of immune checkpoint inhibitors (ICIs) used in oncology are mainly derived from clinical trials or cancer-specific reviews. We aim to analyze ADRs that occurred in patients treated with ICIs in real life.

Materials and methods

We conducted an observational study on a historical cohort of the University Hospitals of Lyon. All patients who initiated an ICI treatment for any cancer in 2017 were included. Patients were followed from the first infusion until 90 days after the last one, death, date of last news or end of the study period (28 February 2019), whichever came first. Two pharmacovigilance specialists assessed the accountability and the severity of each ADR using Naranjo algorithm and common terminology criteria for adverse events (CTCAE) classification, respectively.

Results

248 patients were included. They were treated with anti-PD-(L)-1, mainly nivolumab (70.6%) and pembrolizumab (25.8%). Lung cancer (62.1%) and melanoma (20.2%) were the most represented cancers. 139 ADRs occurred in 93 patients (37.5%), on average at the 6th cure (±6.8). ADRs mainly concerned skin (29.5%), endocrine (19.4%) and digestive (10.8%) systems. 17.3% of ADRs were grades III-V and two patients died because of ADRs. By comparing patients with (N=93) or without (N=155) ADRs, all characteristics appeared similar except for age, number of infusions received and death status. The spontaneous notification rate found in this study was 5.8% for all grade ADRs (N = 8) but raised to 23.8% when only grades higher than III were considered (N = 5).

Discussion/Conclusion

Our results are consistent with literature data in frequency and type of serious ADRs. We found a lower frequency of ADRs of any grade, which could be explained by a fairer causality assessment in our study than in clinical trials.

El texto completo de este artículo está disponible en PDF.

Keywords : Oncology, Immune checkpoint inhibitor, Adverse drug reaction, Real life data, Immunotherapy, Cancer


Esquema


© 2022  Société française de pharmacologie et de thérapeutique. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.